22 results about "Intestines mucosa" patented technology

The present application relates to the technical field of pathological image classification, in particular to an intestinal mucosa tissue pathological image classification method and system based on artificial intelligence. The present application selects a histopathological region from a suspected pathological region, divides a sequence obtained by sequentially arranging the histopathological region into different subsequences, acquires pathological feature templates of the subsequences under each disease category, determines the disease category to which the histopathological region in the subsequence belongs according to the similarity between the texture distribution, blood vessel distribution characteristics of the histopathological region in the subsequence and the pathological feature templates, and acquires the feature templates of each subsequence under each disease category according to the pathological features of the histopathological region belonging to the same disease category and the pathological feature templates of the previous subsequence of each subsequence under each disease category. The present application realizes gradual and accurate matching of the pathological feature templates through dynamic and iterative optimization of the feature templates with the subsequences, and increases the accuracy of pathological feature matching of the intestinal mucosa pathological position.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ackermania muciniphila and recombinant trichina serine protease carried by a derivative of the ackermania muciniphila to preparation of a medicine for treating intestinal inflammation symptoms. According to the present invention, the ackermann muciniphila and the ackermann muciniphila derivative carrying recombinant trichina serine are firstly disclosed, such that the physical barrier of the intestinal mucosa is repaired through the synergistic effect, the expression of TNF-alpha, IL-6, IL-1beta and other proinflammatory factors is specifically regulated and inhibited, the intestinal flora structure is remodeled, and the intestinal inflammation state is significantly improved; experimental results show that the Ackerman muciniphila and the derivative thereof carrying the recombinant trichina serine protease can significantly relieve weight loss of mice with intestinal inflammation induced by DSS, reduce DAI score, and reverse the phenomena of shortened colon and abnormal swelling of spleen. According to the invention, the probiotics and the parasite-derived protein are combined, so that the method has the advantages of high efficiency, safety and easiness in large-scale production, and a new biological preparation strategy is provided for accurate treatment of IBD.

The invention discloses a method for extracting genome DNA (deoxyribonucleic acid) from intestinal mucosa tissue and application, the extraction method comprises the following steps: mixing the intestinal mucosa tissue with lysis buffer, physically homogenizing with a homogenizing rod, precipitating with absolute ethyl alcohol, purifying and collecting DNA, and the tissue lysis buffer contains Tris-HCl, Urea, CHAPS, SDS (sodium dodecyl sulfate) and PMSF. According to the extraction method, DNA can be rapidly and effectively extracted from intestinal mucosa tissues, a foundation is laid for subsequent intestinal mucosa 16S rRNA strain identification, and meanwhile a reference basis is provided for DNA extraction of other tissue samples.

The invention relates to the technical field of pathological image classification, in particular to an intestinal mucosa tissue pathological image classification method and system based on artificial intelligence. The method comprises the following steps: selecting histopathological regions from suspected pathological regions, and dividing a sequence obtained by sequentially arranging the histopathological regions into different subsequences; acquiring a pathological feature template of the sub-sequence under each disease category, and determining the disease category to which the tissue pathological area in the sub-sequence belongs according to the similarity between the texture distribution and blood vessel distribution features of the tissue pathological area in the sub-sequence and the pathological feature template; and according to the pathological feature template of the previous sub-sequence of each sub-sequence under each disease category and the pathological features of the histopathological region belonging to the same disease category, obtaining the feature template of each sub-sequence in each disease category. According to the method, through dynamic iterative optimization of the feature templates along with the subsequences, progressive accurate matching of the pathological feature templates is realized, and the accuracy of pathological feature matching of the pathological positions of the intestinal mucosa is increased.

The application discloses a sophora japonica composition for refractory enteritis and a preparation method and application thereof. The sophora japonica composition for refractory enteritis comprises the following components: sophora japonica, dried orange peel, panax notoginseng, momordica grosvenori and lycoris radiata, and the sophora japonica composition for refractory enteritis is obtained by fermenting plant lactobacillus. The sophora japonica composition for refractory enteritis of the application can obviously increase the amount of duhrlactobacillus, lactobacillus and bifidobacterium and reduce the amount of clostridium in the process of treating inflammatory enteritis; can effectively inhibit the inflammation of colitis, and the mRNA level of inflammatory cytokines TNF-alpha, IL-22, IL-1beta and IL-6 is obviously reduced. The sophora japonica composition can obviously inhibit intestinal inflammation, promote the metabolism of intestinal short-chain fatty acids, increase the thickness of intestinal mucosa, and has obvious curative effects on intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa.

The invention discloses an agaro-oligosaccharide oral solution with a constipation relieving function, and belongs to the technical field of food biology. The invention provides a preparation method of agarotriose. Main components which mainly exert anti-inflammatory activity are analyzed through clinical evaluation. According to the invention, agarotriose is extracted by adopting an enzymolysis method to treat LOP-induced constipation mice, and the influence of main components on model mice is investigated from the aspects of excrement water content, small intestine propulsion rate, first-grain black excrement discharge time, colon pathological structure and the like. Experimental results show that compared with an LOP group, the agarotriose high-dose group can significantly improve constipation symptoms, relieve inflammatory response and promote colonic mucosa repair, so that agarotriose can be used as a good functional food for relieving constipation.

The invention provides a donkey milk exosome preparation, a preparation method and application, and belongs to the technical field of life sciences, the donkey milk exosome preparation comprises a donkey milk exosome and a complex microbial inoculant; wherein the complex microbial inoculant is prepared from clostridium butyricum, bacillus subtilis and enterococcus faecium. The scheme that the donkey milk exosome and the complex microbial inoculant are compounded for use is created for the first time, and the donkey milk exosome and the complex microbial inoculant can achieve synergistic interaction, so that inflammatory factors can be effectively reduced, the number of goblet cells is increased, and the intestinal mucosa is repaired; meanwhile, by utilizing the natural anti-inflammatory property of the donkey milk exosome and the micro-ecological regulation of the complex microbial inoculant, the side effects of chemical drugs are avoided, and an integrated scheme of'intestinal barrier repair-immune regulation 'is provided.

The invention provides an exosome oral soluble film with a multi-targeting function, which is prepared from the following components in parts by weight: 10 to 20 parts of active substances, 20 to 60 parts of carrier materials for wrapping exosomes or drug-loaded exosomes, 50 to 100 parts of film-forming agents, 20 to 40 parts of disintegrating agents, 10 to 25 parts of plasticizers, 1 to 5 parts of flavoring agents and 1 to 10 parts of antioxidants, wherein the active substance is an exosome or a drug-loaded exosome, and the carrier material is a polylactic acid-glycolic acid copolymer-sulfydryl group, polyethylene glycol and polyethylene glycol diacrylate. According to the scheme, the carrier material entrapped with the exosome has a dual targeting effect, so that the exosome or the exosome loaded with the medicine can accurately reach the ulceration position of the colonic mucosa, and accurate treatment is achieved; and the exosome is administrated in an oral dissolution manner, so that a patient can take the exosome with high compliance.

The invention provides an application of a combined composition of antibiotics and bacteria carrying DL-endopeptidase in preparation of a medicine for preventing intestinal development delay of premature infants, the combined composition comprises a component A and a component B which are prepared according to a specific mass ratio, the component A is selected from broad-spectrum antibiotics in an intensive care unit of newborns, and the component B is selected from bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase. And the component B is a strain which can secrete DL-endopeptidase and has endogenous drug resistance to the component A. According to the application, synergism of'clearing 'and'driving' is realized, the traditional clinical thinking of'first sterilization and then remediation 'is broken, pathogenic microorganisms (such as klebsiella and staphylococcus aureus) in a premature infant body are cleared through antibiotics, and meanwhile, bacterial components in the components are synchronously utilized to down-regulate protein expression of the intestinal mucosa intracellular cylindricity disease, so that the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease, and the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease. The synthesis of tight junction protein is actively realized.

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

The application provides a preparation method and application of a polygonatum cyrtonema acid polysaccharide, and belongs to the technical field of polygonatum cyrtonema polysaccharide extraction. The application adopts a separation and purification method of anion exchange chromatography combined with gel chromatography, and finally obtains a polygonatum cyrtonema acid uniform polysaccharide (PCPA) with high purity. In-vivo pharmacodynamic experiments show that the prepared PCPA can significantly relieve intestinal mucosa injury and has high intestinal immune regulation activity. The preparation method provided by the application is stable in process, the prepared polygonatum cyrtonema acid polysaccharide is high in purity, is a uniform polysaccharide, and has an intestinal immune regulation effect.

The application belongs to the technical field of heparin extraction, and particularly relates to a method for determining the abundance of high anti-IIa activity heparin of pig small intestinal mucosa. The method comprises the following steps: (1) crushing fresh pig small intestinal mucosa; (2) using a PowerSoil kit to lyse the mucosa cells crushed in step (1), and performing water bath at 50-65 DEG C for 10-20 min, and then adding an elution buffer to elute the DNA; (3) using PCR to amplify the eluted DNA solution; (4) using a Nextera XT DNA library preparation kit to construct a library, and then using an Illumina NovaSeq 6000 sequencer to perform high-throughput sequencing; (5) using a DADA2 process to denoise and remove chimeric sequences, and using a 97% similarity threshold to cluster to generate OTU, and using a Greengenes database to annotate; (6) then using an LEfSe algorithm to screen differential flora, and using a random forest model to predict heparin activity.

The invention belongs to the field of biomedical materials, targeted drug delivery technologies and ulcerative colitis treatment, and discloses a curcumin-loaded composite microneedle capable of being clamped and a preparation method of the curcumin-loaded composite microneedle. The curcumin-loaded composite microneedle comprises a curcumin-loaded gelatin hemispheroid substrate and a curcumin-loaded chitosan-polyvinyl alcohol microneedle, the microneedle is positioned on the circular end surface of the hemispheroid base; the curcumin in the substrate and the curcumin in the microneedle are loaded in the form of a curcumin-cyclodextrin inclusion compound. The composite microneedle capable of being clamped is formed by designing the hemispheroid substrate and the microneedle array, curcumin is loaded on the hemispheroid substrate and the microneedle part of the composite microneedle, intestinal wall and intestinal mucosa injuries caused by ulcerative colitis can be relieved and treated, intestinal flora disorder and abnormal activation of an inflammatory immune system are indirectly inhibited, and the curative effect of ulcerative colitis is improved. The technical problem that the cure rate of ulcerative colitis is low is solved, and a treatment strategy for targeting intestinal diseases with higher safety and high efficiency is provided.

The application discloses a traditional Chinese medicine micro-capsule enteric-coated tablet for promoting intestinal mucosa repair and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine pharmacy, and comprises a micro-capsule tablet core and an enteric-coated layer coated on the outer surface of the micro-capsule tablet core, wherein the micro-capsule tablet core comprises microcapsules with white-bark tree gum liquid as a wall material and Chinese herbal medicine extract as a core material, the Chinese herbal medicine extract comprises water-soluble inclusion compounds prepared by extracting aloe emodin, Danshen, processed ginger, Sanqi and spina date seed and then being wrapped by beta-cyclodextrin, and active polysaccharide retentate prepared by extracting Herba Baphicacanthis, fried coix seed, white peony root, licorice, Fructus Mume, Astragalus and dendrobium by complex enzymolysis and then being separated by ultrafiltration, and the white-bark tree gum liquid is prepared by swelling white-bark tree in cold water and then being treated by high-pressure homogenization; the micro-capsule is adsorbed on an intestinal ulcer surface to form a physical isolation barrier, and the ultrafiltration detoxification and cyclodextrin wrapping process improves the utilization degree and safety of active ingredients at a target site.

The invention belongs to the technical field of biological medicines, and discloses application of berberine as a prophylactic agent in preparation of a medicine for preventing 5-fluorouracil induced intestinal mucosal injury. Based on the natural advantages of multiple targets and low toxicity of berberine, berberine is used as a preventive for preventing 5-FU induced intestinal mucosal injury for the first time, a core injury mechanism is targeted through a pre-administration mode, novel prevention and treatment strategies and drug candidates are provided for clinic, and the berberine has important clinical conversion value and application prospects. The prevention effect of berberine pre-administration on 5-fluorouracil induced intestinal mucosal injury is disclosed for the first time, and a brand-new clinical treatment mode of berberine is developed. As a natural product, berberine has good human body tolerance and relatively high safety, does not affect the anti-tumor curative effect of 5-fluorouracil when being combined with 5-fluorouracil, shows a certain anti-tumor effect in animal experiments, and is expected to improve the chemotherapy dose intensity and patient compliance.

The invention belongs to the technical field of bioactive peptides, and provides a small red bean polypeptide for preventing and treating ulcerative colitis and application of the small red bean polypeptide, and the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP. The small red bean polypeptide can significantly reduce the DAI score of a mouse with DSS colitis, relieve the shortening of the colon length of the mouse with DSS colitis and improve the erosion and ulcer degree of the colonic mucosa, and has good prevention and treatment effects on ulcerative colitis; meanwhile, the preparation method is simple and easy for industrial production; certain drug research and development and clinical application values are realized.

The utility model discloses an efficient enzymolysis reaction device for extracting pig intestine mucosa protein, which belongs to the technical field of animal product processing, and adopts the technical scheme that the efficient enzymolysis reaction device comprises a reaction tank, a heating mechanism is arranged on the inner wall of the reaction tank, a control mechanism is mounted on the left side of the heating mechanism, and a reaction cover is clamped at the top of the reaction tank; a servo motor is mounted at the top of the reaction cover, a connecting rotating rod is rotationally connected to the bottom of the reaction cover, a connecting rotating shaft is connected to the top of the connecting rotating rod through a flat key, stirring blades are welded to the surface of the connecting rotating rod, and a discharging pipe is fixedly connected to the bottom of the control mechanism. According to the heating mechanism, heat can be uniformly conducted into the reaction tank from the outer side of the reaction tank through cooperation of three heat conduction rings, a heat conduction rod and a heating ring, the local overheating or supercooling phenomenon caused by a traditional heating mode is avoided, the enzymolysis reaction is conducted in a stable temperature environment, the enzyme activity is guaranteed, and the extraction efficiency and quality of pig intestine mucosa protein are improved.

According to the xanthoxylin WGX-50-containing medicine for treating radiation enteritis and the application of the xanthoxylin WGX-50-containing medicine, the direct killing effect of rays on intestinal mucosa can be effectively prevented, the level of cell apoptosis and necrosis can be reduced, and intestinal mucosa ulcer shedding and inflammation infiltration after radiotherapy can be remarkably relieved, so that the toxic and side symptoms of radiotherapy are effectively relieved, and the treatment effect of radiation enteritis is improved. The production of active oxygen and inflammatory factors in the intestinal tract can be effectively reduced, and the damage of oxidative stress to the structure and function of the intestinal tract tissue is prevented, so that dual-mechanism support is provided for protecting the intestinal tract from radiation injury.

The application discloses a whey protein production and health management integrated intelligent system and a control method, relates to the technical field of industrial internet and digital health, and is used for solving the problems that individual intestinal metabolism difference leads to poor absorption of whey protein and industrial production cannot dynamically adapt. First, the intestinal mucosa osmotic pressure sequence and the specific amino acid flux sequence are extracted for time sequence synchronization correlation, and an individual intestinal absorption constraint matrix is constructed. Then, based on the constraint matrix, the upper limit threshold of molecular weight and the release proportion of free amino acid are extracted, and a target peptide chain distribution topology graph is matched and generated. The discrete production control stack is generated by analyzing the topology graph, the bottom controller sequence is overwritten through the industrial intelligent gateway, and the physical equipment is driven to accurately customize the whey protein liquid. Finally, the secondary physiological characteristics are acquired to generate an absorption lag compensation factor, the node correction of the next batch of enzymatic feeding time stamp is performed, and a closed-loop system of physiological feedback driving industrial production line parameter evolution is constructed.

The invention belongs to the technical field of biological medicine, and particularly relates to an electronegative mesoporous SiO2 nanoparticle-insoluble drug collaborative delivery system as well as a preparation method and application thereof. Specifically, the delivery system takes electronegative mesoporous SiO2 nanoparticles as a carrier, and the electronegative mesoporous SiO2 nanoparticles are loaded with an indissolvable drug; wherein the electronegative mesoporous SiO2 nano particles are prepared by adopting a surfactant template method. The delivery system significantly improves the bioavailability of the poorly soluble oral drug by inducing reversible intestinal barrier leakage. Controllable recovery of intestinal barrier leakage can be achieved, the biocompatibility of a system is ensured, medicine is effectively delivered, pathological damage to intestinal mucosa and important organs such as heart, liver, spleen, lung and kidney is avoided, and therefore good practical application value is achieved.

The invention belongs to the technical field of biological medicines, and relates to specific therapeutic activity of a medicinal preparation, in particular to application of ganoderma lucidum exosome-like nanoparticles in preparation of a medicine for treating Parkinson's disease. The preparation method of the lucid ganoderma exosome-like nanoparticles comprises the following steps: crushing, soaking and grinding lucid ganoderma to break lucid ganoderma cells, so as to obtain a lucid ganoderma treatment solution; filtering the lucid ganoderma treatment liquid; wherein the filtration comprises ultrafiltration, the particle size of an ultrafiltration product is 30-400 nm, and the ultrafiltration product is the ganoderma lucidum exosome-like nano-particles. Experimental research shows that the ganoderma lucidum exosome-like nanoparticles can significantly improve intestinal disorder and intestinal mucosa injury of Parkinson rats, and improve motor and cognitive impairment.